As Omicron Surges, FDA’s Vaccine Technique Referred to as Into Query
In other words, from a risk-benefit perspective, it is more logical to continue infusing monoclonal antibodies, even if they are only marginally effective, and to discontinue childhood vaccinations immediately.
The CDC and FDA’s mystifying position can only be the result of their systematic rejection of any possibility of adverse vaccine events, despite the vast and growing evidence to the contrary.
Extract from Children’s Health Defense.
When Omicron got surges, the FDA’s vaccine strategy was called into question
Madhava Setty, MD
The Omicron variant is the predominant COVID-19 strain in the United States, causing the spread of certain ineffective monoclonal antibody therapies to be disrupted. But the urge for vaccines, which are also ineffective against the variant, continues unabated.
The first case of Omicron in the US was reported on December 1, 2021. According to estimates by the Centers for Disease Control and Prevention (CDC) on December 25, 2021, Omicron accounts for 58.6% of SARS-CoV-2 infections in the USA
The rapid emergence of Omicron is an indication of the increased portability of the variant and the ineffectiveness of vaccines against this strain.
The predominance of the Omicron variant caused the Office of the Assistant Secretary of the U.S. Department of Health (HHS) to suspend the allocation of two commonly used monoclonal antibody therapy combinations – Bamlanivimab / Etesevimab (Eli Lilly) and REGN10933 / REGN10987 (Regeneron.) – in Regions of the country with a prevalence of more than 80% of the Omicron variant.
According to HHS “these two products are not expected to be effective in patients infected with the Omicron variant …”
